The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Capmatinib and Tepotinib for MET Exon 14 Mutant Lung Cancer: Selective MET Inhibitors

Targeted oral therapy for MET exon 14 skipping mutations representing actionable oncogenic driver in NSCLC

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Capmatinib and Tepotinib for MET Exon 14 Mutant Lung Cancer: Selective MET Inhibitors?

MET (mesenchymal-epithelial transition) is receptor tyrosine kinase activated by hepatocyte growth factor regulating cell proliferation and motility.

MET exon 14 skipping mutations disrupt juxtamembrane domain Y1003 site preventing receptor ubiquitination and degradation.

Capmatinib (INC280) and tepotinib (MSC2156119J) are highly selective ATP-competitive MET inhibitors with similar mechanisms.

FDA approval is for metastatic NSCLC harboring MET exon 14 mutations as detected by FDA-approved companion diagnostics.

MET amplification represents distinct alteration with different therapeutic implications and may co-occur with exon 14 mutations.

Symptoms

Peripheral edema is most common adverse effect occurring in majority of patients requiring monitoring and supportive measures.
Nausea and decreased appetite affect quality of life requiring antiemetic prophylaxis and nutritional support.
Hepatotoxicity with transaminase elevation requires baseline and serial monitoring with dose modification.
Venous thromboembolism risk increases requiring prophylactic anticoagulation consideration in higher-risk patients.
Pneumonitis represents serious adverse event requiring respiratory symptom monitoring and prompt intervention.

Risk Factors

Older age and never-smoker status correlate with MET exon 14 mutation prevalence in NSCLC.
Prior immunotherapy or chemotherapy exposure may affect treatment selection and response patterns.
Concurrent MET amplification or other resistance alterations may attenuate single-agent MET inhibitor benefit.
Pre-existing edema, heart failure or fluid retention conditions may worsen with MET inhibitor therapy.
Pre-existing pulmonary disease, prior chest radiation may affect ILD risk and tolerability.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Newly diagnosed metastatic NSCLC adenocarcinoma should undergo molecular testing including MET exon 14 analysis.
  • Disease progression with MET exon 14 mutation in advanced setting warrants targeted therapy consideration.
  • Severe peripheral edema, dyspnea or signs of fluid overload require evaluation and treatment modification.
  • Significant transaminase elevation, jaundice or hepatotoxicity require urgent oncology evaluation.
  • New respiratory symptoms during treatment require evaluation distinguishing pneumonitis from progression or infection.

Treatment Methods

01
Capmatinib 400 mg twice daily continuous dosing represents standard regimen with food state recommendations.
02
Tepotinib 450 mg once daily continuous dosing serves as alternative with similar efficacy profile.
03
Edema management with leg elevation, compression stockings, sodium restriction and diuretics when needed.
04
Liver function monitoring at baseline, every 2 weeks for first 3 months then monthly with appropriate dose modification.
05
Comprehensive supportive care including thromboembolism risk assessment, edema management, nutrition support and patient education supports successful long-term therapy administration in this molecularly defined patient population.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.